The group's principal activities are to develop gene therapy products utilizing adenoviral and lentiviral vector technologies. The products of the group are for the treatment of hemophilia, cancer, HIV, aids and other genetic disorders. The two vector products are clinical trials of product candidate for peripheral vascular disease and other technologies and potential products - maximum-ad, dual-ad and il-3 . The group operates only in domestic market. The group is in the development stage. Genstar therapeutics corporation and vascular genetics inc merged to form corautus genetics inc effective as of 05-Feb-2003.
